Home

muzici Decrementați Ie ucdai score calculator Faceți treburile casnice vestă Septembrie

Use of the ulcerative colitis endoscopic index of severity and Mayo  endoscopic score for predicting the therapeutic effect of mesalazine in  patients with ulcerative colitis - ScienceDirect
Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis - ScienceDirect

Cochrane
Cochrane

Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially  Expressed in Ulceration-Associated Myofibroblasts - The American Journal of  Pathology
Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially Expressed in Ulceration-Associated Myofibroblasts - The American Journal of Pathology

A comparison of physician-rated disease severity and patient reported  outcomes in mild to moderately active ulcerative colitis
A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis

Inflammatory Bowel Disease | Clinical Gate
Inflammatory Bowel Disease | Clinical Gate

Defining Disease Severity in Inflammatory Bowel Diseases: Current and  Future Directions - Clinical Gastroenterology and Hepatology
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions - Clinical Gastroenterology and Hepatology

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in  Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I  Study - Gastroenterology
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study - Gastroenterology

Modifi ed Mayo Disease Activity Index (MMDAI) a | Download Table
Modifi ed Mayo Disease Activity Index (MMDAI) a | Download Table

The Efficacy of the Consumption of n-3 Polyunsaturated Fatty Acids for the  Maintenance of Remission in Patients with Inflammatory Bowel Disease
The Efficacy of the Consumption of n-3 Polyunsaturated Fatty Acids for the Maintenance of Remission in Patients with Inflammatory Bowel Disease

New approaches in the follow-up of patients suffering from inflammatory  bowel diseases
New approaches in the follow-up of patients suffering from inflammatory bowel diseases

Summary of activity indices used for ulcerative colitis | Download Table
Summary of activity indices used for ulcerative colitis | Download Table

Cells | Free Full-Text | A Phase 2a, Multicenter, Randomized, Double-Blind,  Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release  Capsules to Induce Remission in Patients with Active and Mild to Moderate  Ulcerative Colitis
Cells | Free Full-Text | A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis

Metabolites | Free Full-Text | Mucosal Metabolomic Profiling and Pathway  Analysis Reveal the Metabolic Signature of Ulcerative Colitis | HTML
Metabolites | Free Full-Text | Mucosal Metabolomic Profiling and Pathway Analysis Reveal the Metabolic Signature of Ulcerative Colitis | HTML

PDF] Correlation of endoscopic disease severity with pediatric ulcerative  colitis activity index score in children and young adults with ulcerative  colitis | Semantic Scholar
PDF] Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis | Semantic Scholar

Modifi ed Mayo Disease Activity Index (MMDAI) a | Download Table
Modifi ed Mayo Disease Activity Index (MMDAI) a | Download Table

Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate  Left-Sided Ulcerative Colitis or Proctitis | NEJM
Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis | NEJM

Remission endpoints in ulcerative colitis: A systematic review
Remission endpoints in ulcerative colitis: A systematic review

CDAI calculator (Crohn's Disease Activity Index)
CDAI calculator (Crohn's Disease Activity Index)

Disease activity index (Schroeder and colleagues 14 ) | Download Table
Disease activity index (Schroeder and colleagues 14 ) | Download Table

Combined oral and enema treatment with Pentasa (mesalazine) is superior to  oral therapy alone in patients with extensive mild/moderate active  ulcerative colitis: a randomised, double blind, placebo controlled study |  Gut
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study | Gut

Remission endpoints in ulcerative colitis: A systematic review
Remission endpoints in ulcerative colitis: A systematic review

Diagnosis of acute severe colitis
Diagnosis of acute severe colitis

WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents
WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents

Use of the ulcerative colitis endoscopic index of severity and Mayo  endoscopic score for predicting the therapeutic effect of mesalazine in  patients with ulcerative colitis - ScienceDirect
Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis - ScienceDirect

WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents
WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents

Scores on Harvey Bradshaw Index (HB) and Ulcerative Colitis Disease... |  Download Scientific Diagram
Scores on Harvey Bradshaw Index (HB) and Ulcerative Colitis Disease... | Download Scientific Diagram

Systematic review with meta‐analysis: endoscopic and histologic placebo  rates in induction and maintenance trials of ulcerative colitis - Ma - 2018  - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis - Ma - 2018 - Alimentary Pharmacology & Therapeutics - Wiley Online Library